Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Sreek Vemulapalli and Roseann White explain the statistical challenges that can arise while collecting longer-term follow-up data during clinical trials.

While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.

The writing committee says collaborative efforts and patient-level perspective can improve management of pain in this ...

The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

The data are observational but intuitive, say experts. Further work might define where T-TEER’s greatest benefit lies.

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

The findings are disappointing, but questions around intervention timing, patient population, and others remain to be ...

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

The recently approved device simplifies operator manipulations by loading a balloon and filter onto the stent.